Abstract
Objective
Methods
Results
Conclusions
Graphical abstract

Key Words
Abbreviations and Acronyms:
AVR (aortic valve replacement), CABG (coronary artery bypass graft), CD (cluster of differentiation), cDC (classical dendritic cell), CPB (cardiopulmonary bypass), DC (dendritic cell), ECM (extracellular matrix), FS (full median sternotomy), IL (interleukin), IL-1Ra (interleukin-1 receptor antagonist), Inf DC (inflammatory dendritic cell), MICS (minimally invasive cardiac surgery), MMP (matrix metalloproteinase), MMPtot (total matrix metalloproteinases), Mφ (macrophage), NK (natural killer cell), PAOF (postoperative atrial fibrillation), PPS (postpericardiotomy syndrome), RAMT-AVR (right anterior minithoracotomy aortic valve replacement), sAVR (conventional full median sternotomy surgical aortic valve replacement), SSC (side scatter), TGFβ (transforming growth factor-beta), TIMP (tissue inhibitor of metalloproteinases), TIMPtot (total tissue inhibitors of metalloproteinases)
- O'Brien B.
- Burrage P.S.
- Ngai J.Y.
- Prutkin J.M.
- Huang C.C.
- Xu X.
- et al.
- Tsang T.S.
- Barnes M.E.
- Hayes S.N.
- Freeman W.K.
- Dearani J.A.
- Butler S.L.
- et al.
- Bruins P.
- te Velthuis H.
- Yazdanbakhsh A.P.
- Jansen P.G.
- van Hardevelt F.W.
- de Beaumont E.M.
- et al.
- Bruins P.
- te Velthuis H.
- Yazdanbakhsh A.P.
- Jansen P.G.
- van Hardevelt F.W.
- de Beaumont E.M.
- et al.

Methods
Patient Sample Acquisition
Cell Isolation and Flow Cytometry
Cytokines, MMPs, TIMPs, and Transforming Growth Factor-Beta (TGFβ)
Statistical Analysis
Results
Patient Demographics
Characteristic | n = 43 |
---|---|
Age, y, mean ± SD | 62.4 ± 12.9 |
Sex | |
Female | 15 |
Male | 28 |
Intervention | |
CABG | 14 |
Full median sternotomy | |
Aortic valve replacement | 8 |
Full median sternotomy | |
Right anterior mini thoracotomy | 8 |
Mitral valve repair/replacement | 9 |
Right mini thoracotomy | |
CABG + AVR | 1 |
Full median sternotomy | |
ASD repair | 3 |
Right anterolateral mini thoracotomy | |
Coronary artery disease | 17 |
Hypertension | 26 |
Diabetes mellitus type II | 16 |
Dyslipidemia | 25 |
Active tobacco use | 10 |
Positive family history | 1 |
Long standing persistent atrial fibrillation | 1 |
Renal disease (stage III or worse; eGFR <60) | 3 |
Pulmonary fibrosis | 1 |
Chronic obstructive pulmonary disease | 2 |
Benign pulmonary nodule | 1 |
Obstructive sleep apnea | 3 |
Asthma | 2 |
Peripheral arterial disease | 1 |
Previous stroke | 3 |
Cardiovascular event | 5 |
Chronic steroid use | 1 |
Immune-suppressed | 0 |
Preoperative ASA use | 16 |
Preoperative NSAID use | 1 |
Orthopnea | 1 |
Presyncope | 4 |
Syncope | 2 |
NYHA class dyspnea | |
Class I | 9 |
Class II | 15 |
Class III | 6 |
Class IV | 0 |
Preoperative LV dysfunction (by echocardiography) | |
Mild | 5 |
Moderate | 2 |
Severe | 0 |
Postoperative outcomes | sAVR, n = 8 | RAMT-AVR, n = 8 |
---|---|---|
Age, mean ± SD | 68.0 ± 6.68 | 68.9 ± 6.49 |
Sex | ||
Female | 2 | 4 |
Male | 6 | 4 |
Coronary artery disease | 1 | 2 |
Hypertension | 5 | 3 |
Diabetes mellitus type II | 1 | 3 |
Dyslipidemia | 3 | 6 |
Active smoking history | 2 | 0 |
Positive family history | 0 | 0 |
Long standing persistent atrial fibrillation | 1 | 0 |
Renal disease (stage III or worse; eGFR <60) | 1 | 1 |
Lung Disease (any type) | 0 | 0 |
Peripheral arterial disease | 0 | 0 |
Previous stroke | 1 | 1 |
Cardiovascular event | 1 | 1 |
Chronic steroid use | 0 | 0 |
Immune-suppressed | 0 | 0 |
Preoperative aspirin use | 3 | 4 |
Preoperative NSAID use | 0 | 0 |
Orthopnea | 0 | 0 |
Presyncope | 0 | 3 |
Syncope | 0 | 2 |
NYHA class dyspnea | ||
Class I | 1 | 2 |
Class II | 2 | 4 |
Class III | 4 | 2 |
Class IV | 0 | 0 |
Preoperative LV dysfunction (by echocardiography) | ||
Mild | 1 | 0 |
Moderate | 0 | 0 |
Severe | 0 | 0 |
Intraoperative details | ||
Cardiopulmonary bypass time, min, mean ± SD | 90.9 ± 22.3 | 76.9 ± 19.5 |
Aortic crossclamp time, min, mean ± SD | 70.1 ± 20.2 | 60.3 ± 20.7 |
Postoperative outcomes | ||
Death | 0 | 0 |
Stroke | 0 | 0 |
Dialysis | 0 | 0 |
Infection | 0 | 0 |
Prescribed aspirin | 8 | 8 |
Mechanical ventilatory time, h | 13.62 ± 13.02 | 4.93 ± 1.37 |
Postoperative atrial fibrillation | 2 | 2 |
Neutrophils and T Cells Are the Predominant Postoperative Pericardial Immune Cells

Cytokines Populate the Pericardial Space After Surgery, Where IL-6 Is the Predominant Cytokine

The Concentration of MMP-9 and MMP-8 is Highest in the Pericardial Space Postsurgery
TIMP-1 and TIMP-2 Have the Highest Concentration in the Postoperative Pericardial Space
Concentration of TGFβ-1 Is Twice as High at 4 Hours Compared With 48 Hours Postcardiotomy
There Is a Significant Decrease in the MMPtot/TIMPtot in the Pericardial Space After Surgery

The Composition of Postoperative Pericardial Immune Cells Is Different Between Patients Undergoing sAVR and RAMT-AVR


Surgical Approach Can Influence the Concentration of Cytokines and MMPs That Are Present in the Pericardial Space Postoperatively
Discussion
Clinical Significance and Implications
- Bruins P.
- te Velthuis H.
- Yazdanbakhsh A.P.
- Jansen P.G.
- van Hardevelt F.W.
- de Beaumont E.M.
- et al.

Postoperative Pericardial Immune Cells
- Murzi M.
- Cerillo A.G.
- Bevilacqua S.
- Gilmanov D.
- Farneti P.
- Glauber M.
Postsurgical Pericardial Cytokines
Postoperative Pericardial Concentration of MMPs and TGFβ
Postsurgical Pericardial TIMPs and the Ratio of Postoperative Pericardial MMPs to TIMPs
Limitations
Conclusions
Conflict of Interest Statement
Appendix E1



Reagent or resource | Source | Identifier |
---|---|---|
Antibodies | ||
eFluor450 anti-human CD3 | Thermo Fisher Scientific | Cat#: 48-0037-42 |
BV510 anti-human CD45 | BioLegend | Cat#: 304036 |
BV650 anti-human CD1c | BioLegend | Cat#: 331542 |
FITC anti-human CD163 | BioLegend | Cat#: 333618 |
PE anti-human CD19 | BioLegend | Cat#: 392506 |
PerCP-Cy5.5 anti-human CD14 | BioLegend | Cat#: 367110 |
PE-Cy7 anti-human CD64 | BioLegend | Cat#: 305021 |
APC anti-human CD56 | BioLegend | Cat#: 362504 |
APC-Cy7 anti-human CD16 | BioLegend | Cat#: 302018 |
Reagents | ||
GhostDye Red710 Viability Dye | Tonbo Biosciences | Cat#: 13-0871-T100 |
Anti-human FcγR Binding Inhibitor | Thermo Fisher Scientific | Cat#: 14-9161-73 |
Dextran powder | Spectrum Chemical | Cat#: 9004-54-0 |
123count eBeads Counting Beads | Thermo Fisher Scientific | Cat#: 01-1234-42 |
Compensation Beads | Invitrogen | Cat#: Q1-2222-42 |
Vacuette NH Sodium Heparin tubes | Greiner bio-one | Cat#: 456028 (6 mL) Cat#: 455051 (9 mL) |
Software | ||
FlowJo10 | Becton Dickinson & Company (BD) | www.flowjo.com |
GraphPad Prism v9.0 | GraphPad Software | www.graphpad.com |
BioRender | BioRender | www.biorender.com |
Adobe Illustrator 2022 | Adobe | www.adobe.com/ca/products/illustrator |
n = 43 | |
---|---|
Coronary artery bypass grafts | |
×2 | 2 |
×3 | 11 |
×4 | 1 |
Valve replacements | |
Aortic valve | 16 |
Mitral valve | 1 |
Valve repairs | |
Aortic valve | 0 |
Mitral valve | 8 |
ASD patch | 3 |
Cardiopulmonary bypass time, min, mean ± SD | 100.8 ± 37.6 |
Aortic crossclamp time, min, mean ± SD | 78.9 ± 31.7 |
References
- Postoperative atrial fibrillation following open cardiac surgery: predisposing factors and complications.J Cardiovasc Thorac Res. 2013; 5: 101-107
- Postpericardiotomy syndrome after cardiac surgery.Ann Med. 2020; 52: 243-264
- Postoperative atrial fibrillation following cardiac surgery: from pathogenesis to potential therapies.Am J Cardiovasc Drugs. 2020; 20: 19-49
- Incidence and outcome of re-entry injury in redo cardiac surgery: benefits of preoperative planning.Eur J Cardiothorac Surg. 2015; 47: 819-823
- Postoperative atrial fibrillation significantly increases mortality, hospital readmission, and hospital costs.Ann Thorac Surg. 2014; 98 (discussion 33): 527-533
- Adverse events and survival with postpericardiotomy syndrome after surgical aortic valve replacement.J Thorac Cardiovasc Surg. 2020; 160: 1446-1456
- Society of Cardiovascular Anesthesiologists/European Association of Cardiothoracic Anaesthetists Practice Advisory for the management of perioperative atrial fibrillation in patients undergoing cardiac surgery.J Cardiothorac Vasc Anesth. 2019; 33: 12-26
- Post-pericardiotomy syndrome: insights into neglected postoperative issues.Eur J Cardiothorac Surg. 2022; 61: 505-514
- Post-operative adhesions: a comprehensive review of mechanisms.Biomedicines. 2021; 9: 867
- Clinical and echocardiographic characteristics of significant pericardial effusions following cardiothoracic surgery and outcomes of echo-guided pericardiocentesis for management: Mayo Clinic experience, 1979-1998.Chest. 1999; 116: 322-331
- Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery.J Am Coll Cardiol. 2008; 51: 793-801
- Inflammatory and antioxidant gene transcripts: a novel profile in postoperative atrial fibrillation.Semin Thorac Cardiovasc Surg. 2021; 33: 948-955
- Atrial myocyte NLRP3/CaMKII nexus forms a substrate for postoperative atrial fibrillation.Circ Res. 2020; 127: 1036-1055
- CD8+CD28null T lymphocytes are associated with the development of atrial fibrillation after elective cardiac surgery.Thromb Haemost. 2020; 120: 1182-1187
- Postoperative atrial fibrillation: mechanisms, manifestations and management.Nat Rev Cardiol. 2019; 16: 417-436
- Mitochondrial DAMPs are released during cardiopulmonary bypass surgery and are associated with postoperative atrial fibrillation.Heart Lung Circ. 2018; 27: 122-129
- Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia.Circulation. 1997; 96: 3542-3548
- Narrative review of the systemic inflammatory reaction to cardiac surgery and cardiopulmonary bypass.Artif Organs. 2022; 46: 568-577
- Characteristics of interleukin-6 signaling in elective cardiac surgery—a prospective cohort study.J Clin Med. 2022; 11: 590
- Inflammatory response and endothelial dysfunction following cardiopulmonary bypass: pathophysiology and pharmacological targets.Recent Pat Inflamm Allergy Drug Discov. 2019; 13: 158-173
- Biomarkers for adverse lung injury following pediatric cardiopulmonary bypass.Crit Care Explor. 2021; 3: e0528
- Magnitude of the inflammatory response to cardiopulmonary bypass and its relation to adverse clinical outcomes.Inflamm Res. 2002; 51: 579-586
- Pulmonary dysfunction after cardiac surgery.Chest. 2002; 121: 1269-1277
- Delirium after cardiac surgery. Incidence, phenotypes, predisposing and precipitating risk factors, and effects.Heart Lung. 2018; 47: 408-417
- AdipoRon attenuates inflammation and impairment of cardiac function associated with cardiopulmonary bypass-induced systemic inflammatory response syndrome.J Am Heart Assoc. 2021; 10: e018097
- Impact of corticosteroids on cardiopulmonary bypass induced inflammation in children: a meta-analysis.Ann Thorac Surg. 2021; 112: 1363-1370
- Delirium and depression in cardiac surgery: a comprehensive review of risk factors, pathophysiology, and management.J Cardiac Surg. 2021; 36: 2876-2889
- Increased inflammation in pericardial fluid persists 48 hours after cardiac surgery.Circulation. 2017; 136: 2284-2286
- Acute ischemia alters human pericardial fluid immune cell composition.JACC Basic Transl Sci. 2021; 6: 765-767
- Pericardial mitochondrial DNA levels are associated with atrial fibrillation after cardiac surgery.Ann Thorac Surg. 2021; 111: 1593-1600
- Macrophages in inflammation, repair and regeneration. International.Immunology. 2018; 30: 511-528
- Proteolysis of subendothelial adhesive glycoproteins (fibronectin, thrombospondin, and von Willebrand factor) by plasmin, leukocyte cathepsin G, and elastase.Thromb Res. 2000; 98: 323-332
- Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer.Proc Natl Acad Sci USA. 2020; 117: 21598-21608
- Incidence of postoperative atrial fibrillation in patients undergoing minimally invasive versus median sternotomy valve surgery.J Thorac Cardiovasc Surg. 2013; 146: 1436-1441
- Minimal access versus conventional aortic valve replacement: a meta-analysis of propensity-matched studies.Interact Cardiovasc Thorac Surg. 2017; 25: 624-632
- Right anterior minithoracotomy versus conventional aortic valve replacement: a propensity score matched study.J Thorac Cardiovasc Surg. 2013; 145: 1222-1226
- Traversing the learning curve in minimally invasive heart valve surgery: a cumulative analysis of an individual surgeon's experience with a right minithoracotomy approach for aortic valve replacement.Eur J Cardiothorac Surg. 2012; 41: 1242-1246
- Interleukin-6 and the acute phase response.Biochem J. 1990; 265: 621-636
- The roles of matrix metalloproteinases and their inhibitors in human diseases.Int J Mol Sci. 2020; 21: 9739
- Membrane-bound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenase and serpinase.J Immunol. 2004; 172: 7791-7803
- Circulating mitochondrial DAMPs cause inflammatory responses to injury.Nature. 2010; 464: 104-107
- Role of neutrophil-derived matrix metalloproteinase-9 in tissue regeneration.Histol Histopathol. 2010; 25: 765-770
- Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture.Circulation. 2006; 113: 438-445
- New insights in the regulation of leukocytosis and the role played by leukocytes in septic shock.Verh K Acad Geneeskd Belg. 2001; 63 (discussion 8-41): 531-538
- RhoA determines lineage fate of mesenchymal stem cells by modulating CTGF-VEGF complex in extracellular matrix.Nat Commun. 2016; 7: 11455
- ADAMTS16 activates latent TGF-β, accentuating fibrosis and dysfunction of the pressure-overloaded heart.Cardiovasc Res. 2020; 116: 956-969
- Transforming growth factor-β in myocardial disease.Nat Rev Cardiol. 2022; 19: 435-455
- Metalloproteinases and their inhibitors: potential for the development of new therapeutics.Cells. 2020; 9: 1313
- TIMPs: versatile extracellular regulators in cancer.Nat Rev Cancer. 2017; 17: 38-53
- The role of TIMPs in regulation of extracellular matrix proteolysis.Matrix Biol. 2015; 44-46: 247-254
- MMPs and TIMPs levels are correlated with anthropometric parameters, blood pressure, and endothelial function in obesity.Sci Rep. 2021; 11: 20052
Article info
Publication history
Footnotes
A.F.H. was supported by a Canadian Institutes of Health Research–Vanier Canada Graduate Scholarship, a Killam Foundation Doctoral Award, an Alberta Innovates: Health Solutions Doctoral Scholarship, and a Kertland Family Doctoral Award. F.I.S. was supported by the Biomedical Education Program (BMEP), funded by the German Academic Exchange Service (DAAD). J.F.D. hold a Canada Research Chair in Translational Immuno-Cardiology.
Drs Fatehi Hassanabad and Schoettler contributed equally to this article.
Drs Fedak and Deniset are cosenior authors for this article.
Data availability statement: The authors confirm that the data presented in the manuscript are contained herein.
Identification
Copyright
User license
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy